The Effect of Long-term Statin Therapy on COVID-19 risk groups
Research type
Research Study
Full title
The Effect of Long-term Statin Therapy on COVID-19 risk groups- a retrospective cohort study
IRAS ID
285075
Contact name
Christine Inwang
Contact email
Sponsor organisation
Homerton University Hospital NHS Foundation Trust
Duration of Study in the UK
5 years, 0 months, 1 days
Research summary
In SARS-Cov-2 infection raised inflammatory markers ( the body's response to injury and infection) play a significant role in causing organ failure and subsequently death). Certain patient groups are of particularly high risk , such as patients with Diabetes, High blood pressure , coronary artery disease (disease in which the blood supply to the heart is compromised) . Also sex and ethnicity has shown to play a role.
Interleukin 6 (IL-6) is one of the key inflammatory markers raised in COVID-19. Statins that is widely used in primary and secondary prevention of coronary artery disease have been documented to have a significant effect on IL-6 levels implicated in the inflammatory process in atherosclerosis ( narrowing of the blood vessels) .
We want to see whether chronic statin treatment offers protection in COVID-19 and particularly in high risk groups.REC name
Social Care REC
REC reference
20/IEC08/0022
Date of REC Opinion
9 Jul 2020
REC opinion
Further Information Favourable Opinion